By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Aldeyra Therapeutics 

15 New England Executive Park

Burlington  Massachusetts  01803  U.S.A.
Phone: 617-513-9882 Fax: N/A


SEARCH JOBS

Aldeyra Therapeutics is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules. The company's lead product, NS2, is an aldehyde trap in development for ocular and systemic inflammation, as well as for Sjögren-Larsson Syndrome and Succinic Semi-Aldehyde Dehydrogenase Deficiency, two inborn errors of aldehyde metabolism.

YEAR FOUNDED:

2004

LEADERSHIP:

FOUNDERS: Thomas A. Jordan and John E. Dowling

CEO: Todd C. Brady

CMO: David J. Clark

CFO: Stephen Tulipano

JOB OPPORTUNITY:

Please click here for Aldeyra job opportunities..

CLINICAL TRIAL:

Please click here for clinical trial information..


Key Statistics


Email: dburke@theruthgroup.com
Ownership: Public

Web Site: Aldeyra
Employees:
Symbol: ALDX
 




Segment
Biotechnology





Company News
Aldeyra (ALDX) Announces Third Quarter 2016 Financial Results 11/15/2016 10:57:16 AM
Aldeyra (ALDX) Announces Presentation Of Phase 2 Allergic Conjunctivitis Results At The 2016 American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting 11/10/2016 7:10:17 AM
Aldeyra (ALDX) Provides Update On Late-Stage Clinical Trials At 2016 Research And Development Day 9/26/2016 9:23:37 AM
Aldeyra (ALDX) Appoints Richard H. Douglas To Its Board Of Directors 9/15/2016 10:18:24 AM
Aldeyra (ALDX) Announces 2016 Research And Development Day 9/12/2016 12:08:44 PM
Aldeyra (ALDX) Announces Second Quarter 2016 Financial Results And Provides Corporate Update 8/10/2016 10:27:49 AM
Aldeyra (ALDX) Announces Positive Results From A Randomized, Double-Blind, Vehicle-Controlled Clinical Trial Of Topical Dermatologic NS2 In Patients With Sjögren-Larsson Syndrome 8/9/2016 11:05:18 AM
Aldeyra (ALDX) Schedules Conference Call To Present Results Of A Randomized, Double-Blind, Vehicle-Controlled Clinical Trial In Sjogren-Larsson Syndrome 8/9/2016 10:58:07 AM
12-Employee Lexington Biotech, Aldeyra (ALDX) Shows Off Positive Drug Trial Data 8/9/2016 6:04:20 AM
Aldeyra Therapeutics (ALDX) To Present At The Canaccord Genuity Annual Growth Conference 8/5/2016 10:44:37 AM
1234567
//-->